Results 131 to 140 of about 250,897 (215)

Antiviral Activity of Pyrazolopyrimidine and Triazolopyrimidine Derivatives Against SARS-CoV-2 In Vitro: Identifying PZP25 as a Promising Scaffold. [PDF]

Pathogens
Sardar S, Martins JSCC, Sousa TC, Silva ASM, Pinto MA, Silveira FF, Silva TB, França RRF, Pinheiro LCS, Boechat N, Siqueira MM, Matos AR, Carvalho LJM.   +12 more
europepmc   +1 more source

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

Biopharmaceutics &Drug Disposition, EarlyView.
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula, Jeevan Sai Kallam, Aarika Kanukolanu, Ganesh Korada, Lakshmi Vineela Nalla   +4 more
wiley   +1 more source

Antiviral Activity of Ethyl Gallate Against Zika Virus: In Vitro and In Silico Studies. [PDF]

Int J Mol Sci
Lee YJ, Kang N, Heo JH, Kim EA, Heo SJ.
europepmc   +1 more source

Design Space Assessment of Virus Inactivation in Plasma‐Derived Matrices Establishes a Single Detergent Alternative to TX‐100‐Containing Mixes

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The detergent Triton X‐100 (TX‐100) is a typical component of solvent/detergent (S/D) mixes applied for virus inactivation steps of biomanufacturing processes, yet environmentally unfavorable properties have led to restrictions on its use. Deviron 13‐S9 has recently been described as an eco‐friendly TX‐100 alternative, with powerful virus ...
Johanna Kindermann, Cecilie Klausen, Michael Karbiener, Thomas R. Kreil   +3 more
wiley   +1 more source

A Novel Small-Molecule TLR7 Agonist AXC-715 Stabilizes TLR7 Dimerization and Exhibits Broad-Spectrum Antiviral Activity. [PDF]

Microorganisms
Yao C, Du MH, Ma YJ, Wang H, Hang L, Li ZC, Yang HY, Yang GY, Wang MD, Ming SL.   +9 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

Engineering Two-Dimensional Nanobody-Origami Architectures for Enhanced Antiviral Activity. [PDF]

Nano Lett
Song T, Galván Achi J, Anirudhan V, Gandavadi D, Le LTP, Hammound KC, Morshed M, Wang X, Rong L, Wang X.   +9 more
europepmc   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Phloretin targeting the 3CLpro Cys144 exhibits broad-spectrum antiviral activity against swine enteric coronavirus. [PDF]

Virol Sin
Xiao J, Guo D, Xing X, Jiang L, Qi S, Wang J, Bai W, Yu S, Shen F, Guo X, Wang X, Zhou W, Li H, Zhao F, Feng L, Zhang J, Xu Y, Yang D, Liu H, Sun D.   +19 more
europepmc   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source